Heidelberg Pharma and Chiome Bioscience Sign Exclusive, TargetSpecific Research and Option Agreement for the Development of an Antibody Drug Conjugate
Ladenburg, Germany, 13 July 2022 – Heidelberg Pharma AG (FSE: HPHA) and Chiome Bioscience Inc., Tokyo, Japan, (Tokyo: 4583) today announced the signing of an exclusive, target-specific research and option agreement. Heidelberg Pharma Research GmbH signed this collaboration, which will combine one of Chiome’s monoclonal antibodies against one specific target with Heidelberg Pharma’s proprietary ATAC® platform.
Under the terms of the agreement, Chiome will have access to Heidelberg Pharma’s Amanitin toxin-linker platform technology and has an option for an exclusive, target-specific license for global development and commercialization rights to the product candidate resulting from the research collaboration.
Heidelberg Pharma would be eligible to receive an option fee, development- and salesrelated milestone payments of up to 105 million Euro as well as tiered royalties in the midupper single digit range.